This finding is congruent with the results from a real-world evidence study that summarized the effects of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and reported that these agents were more effective in patients aged ≥ 70 years than those aged < 70 years [25]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.